SOURCE: Kadmon Corporation

Kadmon Corporation

September 24, 2014 15:00 ET

Kadmon Corporation Announces the Appointment of Dr. Harlan W. Waksal as President and Chief Executive Officer and Dr. Samuel Waksal as Chief of Innovation, Science and Strategy

NEW YORK, NY--(Marketwired - Sep 24, 2014) - Kadmon Corporation, LLC announces today that Harlan W. Waksal, M.D., has joined the Company as its President and Chief Executive Officer after serving as a member of the Company's Board of Managers since April 2014. Dr. Harlan Waksal replaces Samuel D. Waksal, Ph.D., one of the founders of Kadmon, in the Chief Executive role. Dr. Samuel Waksal remains with the Company as Chief of Innovation, Science and Strategy.

Dr. Harlan Waksal brings over 30 years of executive and governance leadership in the life sciences to Kadmon, a tenure which includes the co-founding, with Dr. Samuel Waksal, of ImClone Systems Incorporated, now a wholly-owned subsidiary of Eli Lilly and Company. "I look forward to continuing my work with Kadmon in my new role as President and Chief Executive Officer, and building on the foundation of forward-thinking science, clinical research, and product pipeline, including our current clinical candidates, envisioned and put together by Sam and our management team," said Dr. Harlan Waksal. "As we look to the future, it is my goal to ensure that the Company is well-positioned to take advantage of value-building corporate, strategic and financial options."

Dr. Samuel Waksal remains with the Company as Chief of Innovation, Science and Strategy and is now responsible for oversight of Kadmon's clinical development, research, treatment innovation and scientific strategies. "I look forward to continuing Kadmon's scientific and clinical work in my new role, and to pioneering new medicines addressing areas of serious unmet medical need," said Dr. Samuel Waksal. 

While the Company is continuing to explore its strategic and financial opportunities, including an initial public offering, no specific timelines have been set. Dr. Samuel Waksal remains Chairman of the Company and will transition from that role in the event that the Company elects to pursue an initial public offering.

About Kadmon Corporation

Kadmon Corporation, LLC, is a global company built on a 21st-century paradigm for the translation of innovative science into treatment. The company currently offers products and services for the treatment and management of liver diseases, and is pioneering novel medicines in areas of serious disease, including oncology, immunology and infectious, neurodegenerative and ophthalmic diseases. Emphasizing emerging concepts in molecular biology and genomics, Kadmon is developing treatments and treatment combinations that target the metabolomics and signaling pathways associated with disease, with the goal of addressing some of today's most pressing areas of unmet medical need. For more information, visit www.kadmon.com.

This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. No assurance can be given that an initial public offering or other liquidity event will be consummated. The information contained in this press release is believed to be current as of the date of original issue. Kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact Information

  • Contact Information
    David Pitts
    Argot Partners
    212.600.1902
    Email Contact